Cargando…

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

PURPOSE: Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Recently, the overexpression of programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) has been shown to correlate with poor prognosis in many cancers. However, the expression of PD-L1 or PD-1 ligand 2 (PD-L2) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Hae Il, Jeong, Dongjun, Ji, Sanghee, Ahn, Tae Sung, Bae, Sang Ho, Chin, Susie, Chung, Jun Chul, Kim, Hyung Chul, Lee, Moon Soo, Baek, Moo-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266389/ https://www.ncbi.nlm.nih.gov/pubmed/27456947 http://dx.doi.org/10.4143/crt.2016.066

Ejemplares similares

Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor
por: Jung, Hae Il, et al.
Publicado: (2015)

Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis
por: Yasuoka, Hidetaka, et al.
Publicado: (2020)

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
por: Kim, Jung Ryul, et al.
Publicado: (2013)

Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis
por: Kim, Hyunjung, et al.
Publicado: (2019)

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2018)

Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
por: Wang, Jiting, et al.
Publicado: (2021)

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
por: Zeng, Zhen, et al.
Publicado: (2011)

Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
por: Messeha, Samia S., et al.
Publicado: (2021)

Overexpression of PD‐L1 causes germ cells to slough from mouse seminiferous tubules via the PD‐L1/PD‐L1 interaction
por: Fang, Lian, et al.
Publicado: (2022)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
por: Kim, Hae Su, et al.
Publicado: (2016)

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
por: Zhou, Yajuan, et al.
Publicado: (2017)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

PD-L2 based immune signature confers poor prognosis in HNSCC
por: Qiao, Yu, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
por: Song, Moo-Kon, et al.
Publicado: (2019)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Prognostic implications of PD-L1 expression in patients with angiosarcoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
por: Ma, Ke, et al.
Publicado: (2017)

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
por: Qin, Tao, et al.
Publicado: (2015)

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
por: Ma, Li-Jie, et al.
Publicado: (2018)

Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD‐L1 and predicts poor prognosis in B‐cell lymphoma
por: Liu, Xiaoxia, et al.
Publicado: (2020)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Intrahepatic inflammatory IgA(+)PD-L1(high) monocytes in hepatocellular carcinoma development and immunotherapy
por: Sung, Pil Soo, et al.
Publicado: (2022)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes
por: Cheng, Pinyang, et al.
Publicado: (2019)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Tumor–stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2023)

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD‐1/PD‐L1 inhibitors: A systematic review and meta‐analysis
por: Yang, Yao, et al.
Publicado: (2023)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
por: Xiao, Gang, et al.
Publicado: (2019)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
por: Qing, Yi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_68ohjhhgil85t0oab0b0bof99f